Time to Clinically Relevant Fracture Risk Scores in Postmenopausal Women.

ABSTRACT:

Background

Clinical practice guidelines recommend use of fracture risk scores for screening and pharmacologic treatment decisions. The timing of occurrence of treatment-level (according to 2014 National Osteoporosis Foundation guidelines) or screening-level (according to 2011 US Preventive Services Task Force guidelines) fracture risk scores has not been estimated in postmenopausal women.

Methods

We conducted a retrospective competing risk analysis of new occurrence of treatment-level and screening-level fracture risk scores in postmenopausal women aged 50 years and older, prior to receipt of pharmacologic treatment and prior to first hip or clinical vertebral fracture.

Results

In 54,280 postmenopausal women aged 50 to 64 years without a bone mineral density test, the

SUBMITTER: Gourlay ML 

PROVIDER: S-EPMC5474146 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature